Please ensure Javascript is enabled for purposes of website accessibility Contrarian Fund - Janus Henderson Investors - US Investor
For Individual Investors in the US

Contrarian Fund Holdings

Full Portfolio Holdings

(As of October 31, 2024)

% OF INVESTMENTS
Caesars Entertainment Inc 5.58
Vertiv Holdings Co 5.16
Oracle Corp 5.12
Western Alliance Bancorp 3.82
Marvell Technology Inc 3.76
PNC Financial Services Group Inc 3.63
Amazon.com Inc 3.57
Intercontinental Exchange Inc 3.52
Surgery Partners Inc 3.15
UnitedHealth Group Inc 3.15
Advanced Micro Devices Inc 2.84
Sempra 2.70
Dell Technologies Inc 2.68
Taiwan Semiconductor Manufacturing Co Ltd (ADR) 2.62
Capital One Financial Corp 2.59
Argenx SE (ADR) 2.47
Chart Industries Inc 2.42
Monster Beverage Corp 2.17
Globus Medical Inc 2.13
Freeport-McMoRan Inc 2.11
Howmet Aerospace Inc 2.03
Occidental Petroleum Corp 2.01
3M Co 2.01
Workday Inc 1.99
Crown Holdings Inc 1.99
Teleflex Inc 1.99
Sotera Health Co 1.81
Madrigal Pharmaceuticals Inc 1.69
AbbVie Inc 1.62
American Electric Power Co Inc 1.52
Galderma Group AG 1.51
Lantheus Holdings Inc 1.51
Core & Main Inc 1.40
Signet Jewelers Ltd 1.39
Vaxcyte Inc 1.36
Hong Kong Exchanges & Clearing Ltd 1.26
Cullen/Frost Bankers Inc 1.18
Wynn Resorts Ltd 1.00
Ferguson Enterprises Inc/DE 0.96
Beauty Health Co, 1.25%, 10/01/26 0.92
Sportradar Group AG 0.90
Constellium SE 0.87
AST SpaceMobile Inc 0.36
Beauty Health Co 0.34
ASTS US 01Nov24 Call (AMERICAN PHYSICAL) CITI OTC 30 0.00
AMD US 15Nov24 Call (AMERICAN PHYSICAL) BAML OTC 195 0.00
VRT US 15Nov24 Call (AMERICAN PHYSICAL) CITI OTC 150 0.00
ASTS US 15Nov24 Call (AMERICAN PHYSICAL) MS OTC 40 0.00
ASTS US 21Feb25 Call (AMERICAN PHYSICAL) BAML OTC 50 0.00
HWM US 15Nov24 Call (AMERICAN PHYSICAL) MS OTC 115 0.00
AMZN US 15Nov24 Call (AMERICAN PHYSICAL) BAML OTC 210 -0.01
Cash & Equivalents 1.20
Janus Henderson publishes this listing of securities held as of the most recently available disclosure period, which varies depending on the portfolio. Any portion of holdings may be excluded from publication when deemed in the best interest of the portfolio. Securities are reported at market value.
The portfolio data and its presentation here is based on the investment book of record and may differ from the accounting book of record and complete schedules of investments in regulatory filings due to differing accounting and reporting standards.